Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics
Heart Attack Damage Prevented In Mouse Studies
Formerly CMO at Novartis, Tsai fielded numerous offers before deciding to take on the dual Syncona and Forcefield Therapeutics role. 
